Advertisement

Neurological Sciences

, Volume 38, Issue 12, pp 2165–2169 | Cite as

Chronic demyelinating neuropathy with anti-myelin-associated glycoprotein antibody without any detectable M-protein

  • Yuki Sakamoto
  • Toshio Shimizu
  • Shinsuke Tobisawa
  • Eiji Isozaki
Original Article

Abstract

Previous case reports and studies have shown that anti-myelin-associated glycoprotein (MAG) antibody can be detected in patients with polyneuropathy without any detectable M-protein. Nevertheless, the frequency of and related factors have not yet been adequately investigated. The objectives of this study are to examine the prevalence of anti-MAG antibody in patients with demyelinating neuropathy without M-protein and to determine their clinical characteristics. From January, 2004, to September, 2016, consecutive patients with chronic demyelinating neuropathy were recruited. Anti-MAG antibody presence was tested at the first evaluation. We determined the prevalence of anti-MAG antibody without M-protein among included patients and evaluated the clinical characteristics. A total of 44 patients were included in the present study (12 women; median age at first visit 60 years [interquartile range 47–67 years]; median duration between onset and first visit 9 months [3–26 months]). M-protein was found in eight patients (18%) at the first evaluation. Anti-MAG antibody was present in 2 of remaining 36 (5.6 [95% confidence interval 0–13.0] %) patients without M-protein. Patients with anti-MAG antibody exhibited slowly progressive and distal dominant neuropathy with elevated serum IgM levels and refractory to immunotherapy. There were no differences in clinical features between patients having anti-MAG antibody without M-protein, and those with M-protein. One patient with the anti-MAG antibody showed a delayed appearance of M-protein during a 4-year follow-up after diagnosis. The prevalence of the anti-MAG antibody in chronic demyelinating neuropathy without any detectable M-protein was 5.6%. Anti-MAG antibody may be detectable earlier than M-protein.

Keywords

Myelin-associated glycoprotein Anti-MAG antibody Chronic inflammatory demyelinating polyradiculoneuropathy M-protein 

Notes

Compliance with ethical standards

This study was approved by the institutional ethics committee.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Ellie E, Vital A, Steck A, Boiron JM, Vital C, Julien J (1996) Neuropathy associated with “benign” anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases. J Neurol 243:34–43CrossRefPubMedGoogle Scholar
  2. 2.
    Nobile-Orazio E, Manfredini E, Carpo M et al (1994) Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 36:416–424CrossRefPubMedGoogle Scholar
  3. 3.
    Lunn MP, Nobile-Orazio E (2012) Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev:CD002827Google Scholar
  4. 4.
    Kuijf ML, Eurelings M, Tio-Gillen AP et al (2009) Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology 73:688–695CrossRefPubMedGoogle Scholar
  5. 5.
    European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies (2010) Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. J Peripher Nerv Syst 15:185–195CrossRefGoogle Scholar
  6. 6.
    Eurelings M, Moons KG, Notermans NC et al (2001) Neuropathy and IgM M-proteins: prognostic value of antibodies to MAG, SGPG, and sulfatide. Neurology 56:228–233CrossRefPubMedGoogle Scholar
  7. 7.
    Kawagashira Y, Koike H, Ohyama K et al (2015) Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody. J Neurol Sci 348:67–73CrossRefPubMedGoogle Scholar
  8. 8.
    Leger JM, Viala K, Nicolas G et al (2013) Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 80:2217–2225CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Lupu VD, Mora CA, Dambrosia J, Meer J, Dalakas M, Floeter MK (2007) Terminal latency index in neuropathy with antibodies against myelin-associated glycoproteins. Muscle Nerve 35:196–202CrossRefPubMedGoogle Scholar
  10. 10.
    Gabriel JM, Erne B, Bernasconi L et al (1998) Confocal microscopic localization of anti-myelin-associated glycoprotein autoantibodies in a patient with peripheral neuropathy initially lacking a detectable IgM gammopathy. Acta Neuropathol 95:540–546CrossRefPubMedGoogle Scholar
  11. 11.
    Nobile-Orazio E, Latov N, Hays AP et al (1984) Neuropathy and anti-MAG antibodies without detectable serum M-protein. Neurology 34:218–221CrossRefPubMedGoogle Scholar
  12. 12.
    Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ (2000) Distal acquired demyelinating symmetric neuropathy. Neurology 54:615–620CrossRefPubMedGoogle Scholar
  13. 13.
    Tagawa Y, Yuki N, Hirata K (2000) Anti-SGPG antibody in CIDP: nosological position of IgM anti-MAG/SGPG antibody-associated neuropathy. Muscle Nerve 23:895–899CrossRefPubMedGoogle Scholar
  14. 14.
    Van den Berg L, Hays AP, Nobile-Orazio E et al (1996) Anti-MAG and anti-SGPG antibodies in neuropathy. Muscle Nerve 19:637–643CrossRefPubMedGoogle Scholar
  15. 15.
    Kaku DA, England JD, Sumner AJ (1994) Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 117(Pt 5):941–947CrossRefPubMedGoogle Scholar
  16. 16.
    Nobile-Orazio E, Francomano E, Daverio R et al (1989) Anti-myelin-associated glycoprotein IgM antibody titers in neuropathy associated with macroglobulinemia. Ann Neurol 26:543–550CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l. 2017

Authors and Affiliations

  1. 1.Department of NeurologyTokyo Metropolitan Neurological HospitalFuchuJapan
  2. 2.Department of Neurological Science, Graduate School of MedicineNippon Medical SchoolTokyoJapan

Personalised recommendations